Clinical Trials
15
Active:11
Completed:2
Trial Phases
3 Phases
Phase 1:11
Phase 3:1
Not Applicable:1
Drug Approvals
4
CIMA_AEMPS:3
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (84.6%)Not Applicable
1 (7.7%)Phase 3
1 (7.7%)A Phase 3 Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Not Applicable
Not yet recruiting
- Conditions
- Parathyroid DiseasesHypoparathyroidismEndocrine System Diseases
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Ascendis Pharma Bone Diseases A/S
- Target Recruit Count
- 18
- Registration Number
- NCT07081997
Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
- Conditions
- Hypoparathyroidism
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Ascendis Pharma Bone Diseases A/S
- Registration Number
- NCT05654701
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
Phase 3
Completed
- Conditions
- HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Ascendis Pharma Bone Diseases A/S
- Target Recruit Count
- 84
- Registration Number
- NCT04701203
- Locations
- 🇳🇴
Ascendis Pharma Investigational Site, Oslo, Norway
News
No news found